Work

Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps1130

Authors: Cynthia Carol Bamdad, Yuan Yuan, Jennifer M. Specht, Andrew K. Stewart, Benoit J. Smagghe, Stephen Chi-Min Lin, Mark G. Carter, Timothy W. Synold, Paul Henry Frankel, Vishwas Parekh, Danica M. Walkley, L Elizabeth Budde, Qing Liu-Michael, Jac-Leen Nash, Michael J. Nash, Laura M. Reale, Kevin Y. Yi, Teresa Kim, Stanley R. Hamilton, Stephen J. Forman

Institutions: Minerva Biotechnologies (United States), City Of Hope National Medical Center, University of Washington, City of Hope

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281734146

Cites:

Cited by: 10

Related to: 10